Anticoagulation for Stroke Prevention in Atrial Fibrillation
This study is looking at whether taking certain blood thinners (non-vitamin K oral anticoagulants, or NOACs, like edoxaban or apixaban) can prevent strokes and other heart-related problems in people who have had temporary episodes of atrial fibrillation (an irregular heartbeat) due to stress. You might be able to join if you are 55 or older and have had at least one episode of atrial fibrillation after certain surgeries or other stressful events. The researchers will compare people who take these blood thinners to those who do not, to see if the blood thinners reduce the risk of non-hemorrhagic stroke (stroke not caused by bleeding) or other serious cardiovascular events like heart attacks or death.
- Study design
- This is a multinational, randomized, open-label study comparing non-vitamin K oral anticoagulants (NOACs) to no oral anticoagulation. It plans to enroll 2270 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for the duration of the study, until the last participant has been followed for 24 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress
At a glance
Conditions
NCT03968393
Where you'd take part
This study runs at 105 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Aarhus University Hospital
Aarhus, Denmarkno site contact published
Recruiting
Aga Khan University
Karachi, Sindh, Pakistanno site contact published
Recruiting
Amala Institute
Thrissur, Kerala, Indiano site contact published
Not yet recruiting
Amala Institute of Medical Sciences
Thrissur, Kerala, Indiano site contact published
Recruiting
Amphia Ziekenhuis Breda
Breda, Netherlandsno site contact published
Recruiting
ASST Grande Ospedale Metropolitano Niguarda
Milan, Milan, Italyno site contact published
Recruiting
Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo
Alessandria, Italyno site contact published
Recruiting
B and B Hospital
Lalitpur, Nepalno site contact published
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- David Conen, MD, MPH · PRINCIPAL_INVESTIGATOR · Population Health Research Institute
- PJ Devereaux, MD, PhD · STUDY_CHAIR · Population Health Research Institute
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Incidence of Non-hemorrhagic stroke or systemic embolismFor the duration of follow-up, until final follow-up (occurs when the last global participant has been followed for 24 months)
- Incidence of vascular mortality, and non-fatal non-hemorrhagic stroke, myocardial infarction, peripheral arterial thrombosis, amputation, and symptomatic venous thromboembolismFor the duration of follow-up, until final follow-up (occurs when the last global participant has been followed for 24 months)